fda novavax - Search News

Order byBest matchMost fresh

FDA Panel Debates COVID Vaccine Recipe

FDA panel recommends keeping COVID shots targeted to same strain as last year

The advisory committee, which met after the agency rolled out new vaccine guidelines, said companies should tailor their booster doses to the “JN.1” coronavirus lineage.

BioPharma Dive · 24m

· 1h · on MSN

FDA panel debates COVID vaccine recipe as questions swirl about fall shots

MedPage Today · 1h

FDA Panel Recommends Monovalent COVID Vaccine for Next Season

New Trump vaccine policy limits access to COVID shots

The Trump administration said Tuesday it will limit approval for seasonal COVID-19 shots to seniors and others at high risk pending more data on everyone else — raising questions about whether some p...

· 1d

F.D.A. Poised to Restrict Access to Covid Vaccines

· 1d

WA vaccine scientists push back against FDA changes around COVID shots

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the only non-mRNA COVID-19 vaccine with full FDA approval, offering a differentiated alternative amid growing mRNA fatigue.

12h

FDA won’t approve COVID shot for healthy, non-elderly population

The Food and Drug Administration will no longer approve COVID-19 vaccines for healthy people under 65 without rigorous trials.

3don MSN

Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine

Novavax shares jumped more than 15% on Monday after the company secured a long-awaited U.S. regulatory approval for its COVID-19 vaccine, albeit with new conditions, which helped allay some investor concerns over the future of the shot.

3don MSN

RFK Jr. pledged not to upend US vaccine system, but big changes are underway

WASHINGTON — Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by pledging to work within the decades-old federal system for approval and use of vaccines. Yet his regulators are promising big changes that cloud the outlook for what shots might even be available.